StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
9604.SR$104.40+0.00%
Fair $104.40+0.0%

9604.SR

9604.SR

Healthcare / Medical Care FacilitiesSaudi

$104.40

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $104.40Fund rank 38/100 · Data gapFallback financials|
SA 36/D
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $17.9M · quality 80.7/100

Data gap 38/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 84/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

36/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 9604.SRLocal privado en este navegador · 9604.SR
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$209M

P/E

11.4x

↓

EV/EBITDA

7.2x

↓

ROE

23.6%

↑

Gross Margin

36.6%

↓

Debt/Equity

0.06

↓
52-Week Range$104
$97$129

TradingView lightweight chart

9604.SR price, volumen y niveles de valoración

Último $104.40Periodo +16.0%
Fair value: $104.40

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

21.6%

FCF / Net income

0.97x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $83.0M · net income $18.4M · FCF $17.9M

2022-FY → 2025-FY

Gross margin

36.6%— pts

Operating margin

23.3%— pts

Net margin

22.1%— pts

FCF margin

21.6%— pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$83.0M$83.0M$74.4M$65.4M—
Net Income$18.4M$18.4M$16.7M$12.4M—
EBITDA$27.2M$27.2M$22.7M$19.4M—
EPS——8.356.18—
Gross Margin36.6%36.6%36.9%36.8%—
Operating Margin23.3%23.3%24.4%23.5%—
Net Margin22.1%22.1%22.4%18.9%—
Balance Sheet
Debt/Equity0.060.060.070.220.35
Cash Flow
Free Cash Flow$17.9M$17.9M$20.6M$11.0M—
Returns
ROE23.6%23.6%28.1%29.6%—
Valuation
P/E11.3611.3612.93——
EV/EBITDA7.177.179.05——
P/B2.692.693.64——
Growth & Yield
Revenue Growth11.5%11.5%13.9%——
EPS Growth——35.1%——
Dividend Yield2.9%2.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +2.1%

Total return

+2.1%

Start / end P/E

n/dx → n/dx

EPS bridge

8.35 → n/d

Residual

-0.8%

EPS growthn/d
Multiple reratingn/d
Dividend+2.9%
Residual / FX / buybacks / cross-term-0.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.